Search results
Jan 8, 2019 · John Mendelsohn, M.D., president emeritus of The University of Texas MD Anderson Cancer Center and an internationally acclaimed leader in the field of medicine and scientist whose research helped pioneer a new type of cancer therapy, died Jan. 7 at his home in Houston. He was 82.
People also ask
What happened to John Mendelsohn?
Who is John Mendelsohn?
What did John Mendelsohn do before he became a scientist?
How did John Mendelsohn influence the field of Oncology?
John Ned Mendelsohn is an American writer, journalist, musician and graphic designer. Biography. Mendelsohn, who has sometimes spelled his name as Mendelssohn with two s's, was born in Washington but moved with his parents to southern California aged six months.
Jan 11, 2019 · Former MSK physician-scientist John Mendelsohn, who served the institution in multiple roles from 1985 to 1996, died on January 7 from brain cancer. His influence on the field of oncology — as a scientist, mentor, and administrator — was profound.
John Mendelsohn, M.D., 82, president emeritus of MD Anderson, internationally acclaimed leader in the field of medicine and scientist whose research helped pioneer a new type of cancer treatment, died of brain cancer in January at his home in Houston.
Jan 18, 2019 · Dr. John Mendelsohn, who led the prestigious University of Texas MD Anderson Cancer Center through an era of substantial growth, and who, as a scientist, helped pioneer a new type of cancer...
Jan 10, 2019 · Cancer therapy pioneer John Mendelsohn died from glioblastoma, an aggressive form of brain cancer, on Monday (January 7). He was 82. Mendelsohn was known for his development of a monoclonal antibody therapy now used to treat a number of different malignancies.
Jan 23, 2020 · Amongst his many achievements, Dr. John Mendelsohn is recognized for targeting the first receptor tyrosine kinase (RTK) and developing the first anti-epidermal growth factor receptor (EGFR) blocking antibody as a cancer drug, Erbitux (Cetuximab), and revitalizing the field of targeted cancer therapeutics during the 1980s. 1-3 In the decades ...
Related searches
